MA56142B1 - Protéine modifiée séparée vp1 de capside de aav5 - Google Patents

Protéine modifiée séparée vp1 de capside de aav5

Info

Publication number
MA56142B1
MA56142B1 MA56142A MA56142A MA56142B1 MA 56142 B1 MA56142 B1 MA 56142B1 MA 56142 A MA56142 A MA 56142A MA 56142 A MA56142 A MA 56142A MA 56142 B1 MA56142 B1 MA 56142B1
Authority
MA
Morocco
Prior art keywords
aav5
capsid protein
capsid
separate modified
modified capsid
Prior art date
Application number
MA56142A
Other languages
English (en)
Other versions
MA56142A1 (fr
Inventor
Aleksandr Vladimirovich Karabelskii
Dmitry Valentinovich Morozov
Anna Nikolaevna Strelkova
Dmitrij Aleksandrovich Madera
Mariya Pavlovna Perepelkina
Elena Victorovna Urlova
Pavel Mikhailovich Gershovich
Alexandr Vladimirovich Prokofyev
Original Assignee
Llc Anabion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Llc Anabion filed Critical Llc Anabion
Publication of MA56142A1 publication Critical patent/MA56142A1/fr
Publication of MA56142B1 publication Critical patent/MA56142B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte au domaine de la thérapie génique et de la biologie moléculaire. L'invention concerne plus précisément une protéine modifiée séparée vp1 de capside de virus adéno-associé de sérotype 5 (aav5), qui comprend une ou plusieurs substitutions d'acide aminé par rapport à la protéine vp1 de capside aav5 de type sauvage qui permettent d'augmenter l'efficacité de la transduction, ainsi qu'un capside et un vecteur à base de celui-ci.
MA56142A 2019-08-22 2020-08-21 Protéine modifiée séparée vp1 de capside de aav5 MA56142B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019126509A RU2751592C2 (ru) 2019-08-22 2019-08-22 Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
PCT/RU2020/000445 WO2021034222A1 (fr) 2019-08-22 2020-08-21 Protéine modifiée séparée vp1 de capside de aav5

Publications (2)

Publication Number Publication Date
MA56142A1 MA56142A1 (fr) 2023-05-31
MA56142B1 true MA56142B1 (fr) 2023-09-27

Family

ID=74660332

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56142A MA56142B1 (fr) 2019-08-22 2020-08-21 Protéine modifiée séparée vp1 de capside de aav5

Country Status (19)

Country Link
US (1) US20220306696A1 (fr)
EP (1) EP4019642A4 (fr)
JP (1) JP2022545121A (fr)
KR (1) KR20220158674A (fr)
CN (1) CN114981444A (fr)
AR (1) AR119869A1 (fr)
AU (1) AU2020331882A1 (fr)
BR (1) BR112022003389A2 (fr)
CA (1) CA3148964A1 (fr)
CO (1) CO2022001833A2 (fr)
EC (1) ECSP22021725A (fr)
IL (1) IL290802A (fr)
JO (1) JOP20220043A1 (fr)
MA (1) MA56142B1 (fr)
MX (1) MX2022002184A (fr)
PE (1) PE20221254A1 (fr)
RU (1) RU2751592C2 (fr)
TW (1) TW202120690A (fr)
WO (1) WO2021034222A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113121654B (zh) * 2021-04-19 2023-11-17 信念医药科技(上海)有限公司 腺相关病毒衣壳蛋白及包含其的腺相关病毒载体
AR126839A1 (es) * 2021-08-20 2023-11-22 Llc «Anabion» Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta
AR126840A1 (es) 2021-08-20 2023-11-22 Llc «Anabion» Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
EP1453547B1 (fr) * 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Sequences du serotype 8 du virus associe a l'adenovirus (aav), vecteurs les contenant et utilisations correspondantes
EP3693025B1 (fr) 2011-04-22 2021-10-13 The Regents of The University of California Virions de virus adéno-associé avec capside variant et procédés d'utilisation de ceux-ci
MY172457A (en) 2012-04-18 2019-11-26 Childrens Hospital Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
CA3209883A1 (fr) * 2013-07-22 2015-01-29 The Children's Hospital Of Philadelphia Compositions et variants de virus adeno-associes, et methodes et utilisations pour un transfert de genes dans des cellules, des organes et des tissus
US10081659B2 (en) * 2015-04-06 2018-09-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Adeno-associated vectors for enhanced transduction and reduced immunogenicity
SG10202107733QA (en) * 2015-09-28 2021-09-29 Univ North Carolina Chapel Hill Methods and compositions for antibody-evading virus vectors
WO2017201121A1 (fr) * 2016-05-17 2017-11-23 University Of Florida Research Foundation, Inc. Vaa recombiné pour la thérapie génique des poumons

Also Published As

Publication number Publication date
US20220306696A1 (en) 2022-09-29
CA3148964A1 (fr) 2021-02-25
CN114981444A (zh) 2022-08-30
KR20220158674A (ko) 2022-12-01
RU2751592C2 (ru) 2021-07-15
EP4019642A1 (fr) 2022-06-29
AR119869A1 (es) 2022-01-19
MA56142A1 (fr) 2023-05-31
AU2020331882A1 (en) 2022-11-03
JP2022545121A (ja) 2022-10-25
TW202120690A (zh) 2021-06-01
IL290802A (en) 2022-04-01
JOP20220043A1 (ar) 2023-01-30
PE20221254A1 (es) 2022-08-16
WO2021034222A9 (fr) 2021-04-22
RU2019126509A3 (fr) 2021-06-04
RU2019126509A (ru) 2021-06-04
CO2022001833A2 (es) 2022-08-09
WO2021034222A1 (fr) 2021-02-25
ECSP22021725A (es) 2022-08-31
BR112022003389A2 (pt) 2022-05-17
EP4019642A4 (fr) 2023-09-06
MX2022002184A (es) 2022-05-24

Similar Documents

Publication Publication Date Title
MA56142B1 (fr) Protéine modifiée séparée vp1 de capside de aav5
MA46230A (fr) Mutations de protéine d'enveloppe du vih stabilisant la forme trimère
MA43466A1 (fr) Traitements du cancer de l'utérus
MA40794A1 (fr) Nouveaux peptides et combinaisons de peptides et d'échafaudages destinés à être utilisés en immunothérapie contre le carcinome hépatocellulaire (chc) et d'autres cancers
MA51353B1 (fr) Sérotype du virus adéno-associé recombinant hybride entre aav9 et aavrh74 possédant un tropisme hépatique réduit
MA41717A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
MA40813A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
EA202191418A1 (ru) Рекомбинантные вирусные векторы и нуклеиновые кислоты для их получения
MA49513B1 (fr) Vecteurs viraux recombinants au tropisme modifié et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines
MX2022007005A (es) Construcciones de iarn y metodos para inhibir la expresion de lpa.
MA43477A1 (fr) Immunothérapie contre le mélanome et d'autres cancers
BR112021020957A2 (pt) Capsídeos de vírus adenoassociado (aav) variante para liberação intravítrea
MX2023012722A (es) Capsides de aav y usos de las mismas.
EA200601043A1 (ru) Промоторы для экспрессии в модифицированном вирусе осповакцины штамма анкара
MA64618A1 (fr) Protéine modifiée séparée vp1 de capside aav9
MA58655B1 (fr) Acide nucléique optimisé par codons qui code la protéine smn1
MA64619A1 (fr) Protéine modifiée séparée vp1 de capside aav5
EA202092335A1 (ru) Композиции на основе эренумаба и пути их применения
EA202092694A1 (ru) Системы и способы количественного определения и модификации вязкости белков
EA202190853A1 (ru) Связывающие dll3 белки и способы применения
MA47687B1 (fr) Vecteurs de virus adéno-associé de clade f, et leurs utilisations
EA202192936A1 (ru) Варианты капсидов aav для доставки в стекловидное тело
WO2023004407A3 (fr) Compositions de virus adéno-associés et leurs méthodes d'utilisation
EA202090326A1 (ru) Стабилизирующие тример мутации белка оболочки hiv